

NCT ID	NCT05438342
Title	An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis
Phase	Not Applicable
Date Added	2022-06-29
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Chemotherapy?checkpoint immunotherapy, targeted therapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05611034
Title	In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung
Phase	Phase 1
Date Added	2022-11-09
Location	Canada
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	oxaliplatin
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05479812
Title	Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-07-29
Location	Arizona, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States New Jersey, United States New York, United States Oregon, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Pembrolizumab, WTX-124
Tags	MSI-H/ MMRd
NCT ID	NCT05487235
Title	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-08-04
Location	Argentina Australia Brazil Canada Korea, Republic of New Zealand

Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Atezolizumab, GDC-1971, Omeprazole
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05491317
Title	A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2022-08-08
Location	France
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05493683
Title	Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
Phase	Phase 2
Date Added	2022-08-09
Location	China,China,China,China,China,China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Disitamab vedotin, Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04262687
Title	Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
Phase	Phase 2
Date Added	2020-02-10
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT05205330
Title	A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients
Phase	Phase 2
Date Added	2022-01-25
Location	Italy
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	AGEN2034, Balstilimab, CR6086
Tags	MSS/ MMRp

NCT ID	NCT05201612
Title	Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
Phase	Phase 2
Date Added	2022-01-21
Location	Spain
Prior IO Allowed	No
CRC-directed	Yes
Status	Unknown status
Drugs	Olaparib, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT03104439
Title	Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
Phase	Phase 2
Date Added	2017-04-07
Location	Massachusetts, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Ipilimumab, Nivolumab, Opdivo, Yervoy
Tags	MSI-H/ MMRd, MSS/ MMRp